<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INLYTA- axitinib tablet, film coated </strong><br>Pfizer Laboratories Div Pfizer Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA.<br><br> INLYTA<span class="Sup">®</span> (axitinib) tablets for oral administration<br> Initial U.S. Approval:  2012</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless"><tr>
<td align="left">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span> (<a href="#S5.5">5.5</a>)</td>
<td align="right">08/2014</td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">INLYTA is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li> The starting dose is 5 mg orally twice daily. Dose adjustments can be made based on individual safety and tolerability. (<a href="#S2.1">2.1</a>,<a href="#S2.2"> 2.2</a>)</li>
<li> Administer INLYTA dose approximately 12 hours apart with or without food. (<a href="#S2.1">2.1</a>)</li>
<li> INLYTA should be swallowed whole with a glass of water. (<a href="#S2.1">2.1</a>)</li>
<li> If a strong CYP3A4/5 inhibitor is required, decrease the INLYTA dose by approximately half. (<a href="#S2.2">2.2</a>)</li>
<li> For patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, decrease the starting dose by approximately half. (<a href="#S2.2">2.2</a>)</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">1 mg and 5 mg tablets (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> has been observed. Blood pressure should be well-controlled prior to initiating INLYTA. Monitor for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and treat as needed. For persistent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> despite use of anti-hypertensive medications, reduce the INLYTA dose. (<a href="#S5.1">5.1</a>)</li>
<li>Arterial and venous thrombotic events have been observed and can be fatal. Use with caution in patients who are at increased risk for these events. (<a href="#S5.2">5.2</a>,<a href="#S5.3"> 5.3</a>)</li>
<li>Hemorrhagic events, including fatal events, have been reported. INLYTA has not been studied in patients with evidence of untreated brain <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span> or recent active <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> and should not be used in those patients. (<a href="#S5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span> has been observed and can be fatal. Monitor for signs or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> throughout treatment with INLYTA. (<a href="#s5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforation</span> and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span>, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have occurred. Use with caution in patients at risk for <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> or <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span>. (<a href="#S5.6">5.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> requiring thyroid hormone replacement has been reported. Monitor thyroid function before initiation of, and periodically throughout, treatment with INLYTA. (<a href="#S5.7">5.7</a>)</li>
<li>Stop INLYTA at least 24 hours prior to scheduled surgery. (<a href="#S5.8">5.8</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span> (RPLS) has been observed. Permanently discontinue INLYTA if signs or symptoms of RPLS occur. (<a href="#S5.9">5.9</a>)</li>
<li>Monitor for <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> before initiation of, and periodically throughout, treatment with INLYTA. For moderate to severe <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, reduce the dose or temporarily interrupt treatment with INLYTA. (<a href="#S5.10">5.10</a>)</li>
<li>Liver enzyme elevation has been observed during treatment with INLYTA. Monitor ALT, AST and bilirubin before initiation of, and periodically throughout, treatment with INLYTA. (<a href="#S5.11">5.11</a>)</li>
<li>The starting dose of INLYTA should be decreased if used in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. INLYTA has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#S2.2">2.2</a>,<a href="#S5.12"> 5.12</a>)</li>
<li>INLYTA can cause fetal harm when administered to a pregnant woman based on its mechanism of action. Women of childbearing potential should be advised of the potential hazard to the fetus and to avoid becoming pregnant while receiving INLYTA. (<a href="#S5.13">5.13</a>,<a href="#S8.1"> 8.1</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common (≥20%) adverse reactions are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, palmar-plantar erythrodysesthesia (hand-foot) syndrome, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li> Avoid strong CYP3A4/5 inhibitors. If unavoidable, reduce the INLYTA dose. (<a href="#S2.2">2.2</a>,<a href="#S7.1"> 7.1</a>)</li>
<li> Avoid strong CYP3A4/5 inducers. (<a href="#S7.2">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 	Recommended Dosing </a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Modification Guidelines</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> and <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">Hypertensive Crisis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 	Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span> and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">Fistula</span> Formation</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Thyroid Dysfunction</a></h2>
<h2><a href="#section-5.8" class="toc">5.8	<span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing Complications</a></h2>
<h2><a href="#section-5.9" class="toc">5.9	<span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10	<span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> </a></h2>
<h2><a href="#section-5.11" class="toc">5.11	Elevation of Liver Enzymes</a></h2>
<h2><a href="#section-5.12" class="toc">5.12	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13	Pregnancy</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	CYP3A4/5 Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	CYP3A4/5 Inducers</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-15.2" class="toc">17.2	Arterial/Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span></a></h2>
<h2><a href="#section-15.3" class="toc">17.3	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></h2>
<h2><a href="#section-15.4" class="toc">17.4	<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></a></h2>
<h2><a href="#section-15.5" class="toc">17.5	<span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6	Abnormal Thyroid Function</a></h2>
<h2><a href="#section-15.7" class="toc">17.7	<span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing Complications</a></h2>
<h2><a href="#section-15.8" class="toc">17.8   	<span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span></a></h2>
<h2><a href="#section-15.9" class="toc">17.9	Pregnancy</a></h2>
<h2><a href="#section-15.10" class="toc">17.10	Concomitant Medications</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">INLYTA is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 	Recommended Dosing </h2>
<p class="First">The recommended starting oral dose of INLYTA is 5 mg twice daily. Administer INLYTA doses approximately 12 hours apart with or without food <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>. INLYTA should be swallowed whole with a glass of water.</p>
<p>If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Modification Guidelines</h2>
<p class="First">Dose increase or reduction is recommended based on individual safety and tolerability.</p>
<p>Over the course of treatment, patients who tolerate INLYTA for at least two consecutive weeks with no adverse reactions &gt;Grade 2 (according to the Common Toxicity Criteria for Adverse Events [CTCAE]), are normotensive, and are not receiving anti-<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> medication, may have their dose increased. When a dose increase from 5 mg twice daily is recommended, the INLYTA dose may be increased to 7 mg twice daily, and further to 10 mg twice daily using the same criteria.</p>
<p>Over the course of treatment, management of some adverse drug reactions may require temporary interruption or permanent discontinuation and/or dose reduction of INLYTA therapy <span class="Italics">[see<a href="#S5"> Warnings and Precautions (5)</a>]</span>. If dose reduction from 5 mg twice daily is required, the recommended dose is 3 mg twice daily. If additional dose reduction is required, the recommended dose is 2 mg twice daily.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Underline">Strong CYP3A4/5 Inhibitors:</span>  The concomitant use of strong CYP3A4/5 inhibitors should be avoided (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole). Selection of an alternate concomitant medication with no or minimal CYP3A4/5 inhibition potential is recommended. Although INLYTA dose adjustment has not been studied in patients receiving strong CYP3A4/5 inhibitors, if a strong CYP3A4/5 inhibitor must be co-administered, a dose decrease of INLYTA by approximately half is recommended, as this dose reduction is predicted to adjust the axitinib area under the plasma concentration vs time curve (AUC) to the range observed without inhibitors. The subsequent doses can be increased or decreased based on individual safety and tolerability. If co-administration of the strong inhibitor is discontinued, the INLYTA dose should be returned (after 3 – 5 half-lives of the inhibitor) to that used prior to initiation of the strong CYP3A4/5 inhibitor<span class="Italics"> [see<a href="#S7.1"> Drug Interactions (7.1) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span>  No starting dose adjustment is required when administering INLYTA to patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class A). Based on the pharmacokinetic data, the INLYTA starting dose should be reduced by approximately half in patients with baseline moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class B). The subsequent doses can be increased or decreased based on individual safety and tolerability. INLYTA has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class C) <span class="Italics">[see<a href="#S5.12"> Warnings and Precautions (5.12)</a>,<a href="#S8.6"> Use in Specific Populations (8.6)</a>, </span><span class="Italics">and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">1 mg tablets of INLYTA: red, film-coated, oval tablets, debossed with "Pfizer" on one side and "1 XNB" on the other side.</p>
<p>5 mg tablets of INLYTA: red, film-coated, triangular tablets, debossed with "Pfizer" on one side and "5 XNB" on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> and <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">Hypertensive Crisis</span></h2>
<p class="First">In a controlled clinical study with INLYTA for the treatment of patients with RCC, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> was reported in 145/359 patients (40%) receiving INLYTA and 103/355 patients (29%) receiving sorafenib. Grade 3/4 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> was observed in 56/359 patients (16%) receiving INLYTA and 39/355 patients (11%) receiving sorafenib. <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">Hypertensive crisis</span> was reported in 2/359 patients (&lt;1%) receiving INLYTA and none of the patients receiving sorafenib. The median onset time for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (systolic blood pressure &gt;150 mmHg or diastolic blood pressure &gt;100 mmHg) was within the first month of the start of INLYTA treatment and blood pressure increases have been observed as early as 4 days after starting INLYTA. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> was managed with standard antihypertensive therapy. Discontinuation of INLYTA treatment due to <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> occurred in 1/359 patients (&lt;1%) receiving INLYTA and none of the patients receiving sorafenib <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>].</span></p>
<p>Blood pressure should be well-controlled prior to initiating INLYTA. Patients should be monitored for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and treated as needed with standard anti-hypertensive therapy. In the case of persistent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> despite use of anti-hypertensive medications, reduce the INLYTA dose. Discontinue INLYTA if <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is severe and persistent despite anti-hypertensive therapy and dose reduction of INLYTA, and discontinuation should be considered if there is evidence of <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>. If INLYTA is interrupted, patients receiving antihypertensive medications should be monitored for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span><span class="Italics"> [see<a href="#S2.2"> Dosage and Administration (2.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span> </h2>
<p class="First">In clinical trials, arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> have been reported, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. In a controlled clinical study with INLYTA for the treatment of patients with RCC, Grade 3/4 arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> were reported in 4/359 patients (1%) receiving INLYTA and 4/355 patients (1%) receiving sorafenib. Fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span> was reported in 1/359 patients (&lt;1%) receiving INLYTA and none of the patients receiving sorafenib <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>]</span>.</p>
<p>In clinical trials with INLYTA, arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (including transient ischemic attack, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="4334245" conceptname="Retinal artery occlusion">retinal artery occlusion</span>) were reported in 17/715 patients (2%), with two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> secondary to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>.</p>
<p>Use INLYTA with caution in patients who are at risk for, or who have a history of, these events. INLYTA has not been studied in patients who had an arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> within the previous 12 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 	Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span></h2>
<p class="First">In clinical trials, venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> have been reported, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. In a controlled clinical study with INLYTA for the treatment of patients with RCC, venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> were reported in 11/359 patients (3%) receiving INLYTA and 2/355 patients (1%) receiving sorafenib. Grade 3/4 venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> were reported in 9/359 patients (3%) receiving INLYTA (including <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">retinal vein occlusion</span> and <span class="product-label-link" type="condition" conceptid="4187790" conceptname="Thrombosis of retinal vein">retinal vein thrombosis</span>) and 2/355 patients (1%) receiving sorafenib. Fatal <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> was reported in 1/359 patients (&lt;1%) receiving INLYTA and none of the patients receiving sorafenib. In clinical trials with INLYTA, venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> were reported in 22/715 patients (3%), with two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> secondary to <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p>Use INLYTA with caution in patients who are at risk for, or who have a history of, these events. INLYTA has not been studied in patients who had a venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> within the previous 6 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></h2>
<p class="First">In a controlled clinical study with INLYTA for the treatment of patients with RCC, hemorrhagic events were reported in 58/359 patients (16%) receiving INLYTA and 64/355 patients (18%) receiving sorafenib. Grade 3/4 hemorrhagic events were reported in 5/359 (1%) patients receiving INLYTA (including <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4338544" conceptname="Lower gastrointestinal hemorrhage">lower gastrointestinal hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>) and 11/355 (3%) patients receiving sorafenib. Fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> was reported in 1/359 patients (&lt;1%) receiving INLYTA (<span class="product-label-link" type="condition" conceptid="193250" conceptname="Gastric hemorrhage">gastric hemorrhage</span>) and 3/355 patients (1%) receiving sorafenib.</p>
<p>INLYTA has not been studied in patients who have evidence of untreated brain <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span> or recent active <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> and should not be used in those patients. If any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> requires medical intervention, temporarily interrupt the INLYTA dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In a controlled clinical study with INLYTA for the treatment of patients with RCC, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> was reported in 6/359 patients (2%) receiving INLYTA and 3/355 patients (1%) receiving sorafenib. Grade 3/4 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> was observed in 2/359 patients (1%) receiving INLYTA and 1/355 patients (&lt;1%) receiving sorafenib. Fatal <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> was reported in 2/359 patients (1%) receiving INLYTA and 1/355 patients (&lt;1%) receiving sorafenib. Monitor for signs or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> throughout treatment with INLYTA. Management of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> may require permanent discontinuation of INLYTA.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span> and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">Fistula</span> Formation</h2>
<p class="First">In a controlled clinical study with INLYTA for the treatment of patients with RCC, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> was reported in 1/359 patients (&lt;1%) receiving INLYTA and none of the patients receiving sorafenib. In clinical trials with INLYTA, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> was reported in 5/715 patients (1%), including one <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. In addition to cases of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>, <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistulas</span> were reported in 4/715 patients (1%).</p>
<p>Monitor for symptoms of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> or <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span> periodically throughout treatment with INLYTA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Thyroid Dysfunction</h2>
<p class="First">In a controlled clinical study with INLYTA for the treatment of patients with RCC, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> was reported in 69/359 patients (19%) receiving INLYTA and 29/355 patients (8%) receiving sorafenib. <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span> was reported in 4/359 patients (1%) receiving INLYTA and 4/355 patients (1%) receiving sorafenib. In patients who had thyroid stimulating hormone (TSH) &lt;5 μU/mL before treatment, elevations of TSH to ≥10 μU/mL occurred in 79/245 patients (32%) receiving INLYTA and 25/232 patients (11%) receiving sorafenib <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>].</span></p>
<p>Monitor thyroid function before initiation of, and periodically throughout, treatment with INLYTA. Treat <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> according to standard medical practice to maintain euthyroid state.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	<span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing Complications</h2>
<p class="First">No formal studies of the effect of INLYTA on <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing have been conducted.</p>
<p>Stop treatment with INLYTA at least 24 hours prior to scheduled surgery. The decision to resume INLYTA therapy after surgery should be based on clinical judgment of adequate <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	<span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span></h2>
<p class="First">In a controlled clinical study with INLYTA for the treatment of patients with RCC, <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">reversible posterior leukoencephalopathy syndrome</span> (RPLS) was reported in 1/359 patients (&lt;1%) receiving INLYTA and none of the patients receiving sorafenib <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>]</span>. There were two additional reports of RPLS in other clinical trials with INLYTA.</p>
<p>RPLS is a neurological disorder which can present with <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and other visual and neurologic disturbances. Mild to severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may be present. Magnetic resonance imaging is necessary to confirm the diagnosis of RPLS. Discontinue INLYTA in patients developing RPLS. The safety of reinitiating INLYTA therapy in patients previously experiencing RPLS is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	<span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> </h2>
<p class="First">In a controlled clinical study with INLYTA for the treatment of patients with RCC, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> was reported in 39/359 patients (11%) receiving INLYTA and 26/355 patients (7%) receiving sorafenib. Grade 3 <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> was reported in 11/359 patients (3%) receiving INLYTA and 6/355 patients (2%) receiving sorafenib <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>].</span></p>
<p>Monitoring for <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> before initiation of, and periodically throughout, treatment with INLYTA is recommended. For patients who develop moderate to severe <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, reduce the dose or temporarily interrupt INLYTA treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	Elevation of Liver Enzymes</h2>
<p class="First">In a controlled clinical study with INLYTA for the treatment of patients with RCC, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) elevations of all grades occurred in 22% of patients on both arms, with Grade 3/4 events in &lt;1% of patients on the INLYTA arm and 2% of patients on the sorafenib arm.</p>
<p>Monitor ALT, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST) and bilirubin before initiation of and periodically throughout treatment with INLYTA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The systemic exposure to axitinib was higher in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class B) compared to subjects with normal hepatic function. A dose decrease is recommended when administering INLYTA to patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class B). INLYTA has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class C) <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2)</a>,<a href="#S8.6"> Use in Specific Populations (8.6)</a>, and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13	Pregnancy</h2>
<p class="First">INLYTA can cause fetal harm when administered to a pregnant woman based on its mechanism of action. There are no adequate and well-controlled studies in pregnant women using INLYTA. In developmental toxicity studies in mice, axitinib was teratogenic, embryotoxic and fetotoxic at maternal exposures that were lower than human exposures at the recommended clinical dose.</p>
<p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving INLYTA. If this drug is used during pregnancy, or if a patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see<a href="#S8.1"> Use in Specific Populations (8.1)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety of INLYTA has been evaluated in 715 patients in monotherapy studies, which included 537 patients with advanced RCC. The data described <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>] </span>reflect exposure to INLYTA in 359 patients with advanced RCC who participated in a randomized clinical study versus sorafenib <span class="Italics">[see<a href="#S14"> Clinical Studies (14)</a>]</span>.</p>
<p>The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1–5.13)</a>]</span>: <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span> formation, thyroid dysfunction, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing complications, RPLS, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, elevation of liver enzymes, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and fetal development.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">The median duration of treatment was 6.4 months (range 0.03 to 22.0) for patients who received INLYTA and 5.0 months (range 0.03 to 20.1) for patients who received sorafenib. Dose modifications or temporary delay of treatment due to an adverse reaction occurred in 199/359 patients (55%) receiving INLYTA and 220/355 patients (62%) receiving sorafenib. Permanent discontinuation due to an adverse reaction occurred in 34/359 patients (9%) receiving INLYTA and 46/355 patients (13%) receiving sorafenib.</p>
<p>The most common (≥20%) adverse reactions observed following treatment with INLYTA were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, palmar-plantar erythrodysesthesia (hand-foot) syndrome, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Table 1 presents adverse reactions reported in ≥10% patients who received INLYTA or sorafenib.</p>
<a name="table1"></a><table width="80%">
<caption><span>Table 1. Adverse Reactions Occurring in ≥10% of Patients Who Received INLYTA or Sorafenib</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="4" valign="middle">Adverse Reaction<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center" colspan="2">INLYTA </th>
<th class="Rrule" align="center" colspan="2">Sorafenib</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center" colspan="2">(N=359)</th>
<th class="Rrule" align="center" colspan="2">(N=355)</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center">All Grades<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th>
<th class="Rrule" align="center">Grade 3/4</th>
<th class="Rrule" align="center">All Grades<a href="#footnote-2" class="Sup">†</a>
</th>
<th class="Rrule" align="center">Grade 3/4</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">%</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Percentages are treatment-emergent, all-causality events</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">55</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">Dysphonia</span></td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Palmar-plantar erythrodysesthesia syndrome</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">16</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span></td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucosal inflammation</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
</tbody>
</table>
<p>Selected adverse reactions (all grades) that were reported in &lt;10% of patients treated with INLYTA included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (9%), <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> (8%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (7%), <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> (6%), <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> (6%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (4%), <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span> (4%), <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (3%), <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> (3%), lipase increased (3%), <span class="product-label-link" type="condition" conceptid="441334" conceptname="Glossodynia">glossodynia</span> (3%), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (2%), <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span> (2%), <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span> (2%), <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (1%), retinal-vein occlusion/<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> (1%), <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span> (1%), and transient ischemic attack (1%).</p>
<p>Table 2 presents the most common laboratory abnormalities reported in ≥10% patients who received INLYTA or sorafenib.</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2. Laboratory Abnormalities Occurring in ≥10% of Patients Who Received INLYTA or Sorafenib</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="3" valign="middle">Laboratory Abnormality</th>
<th class="Rrule" align="center" rowspan="3" valign="middle">N</th>
<th class="Rrule" align="center" colspan="2">INLYTA</th>
<th class="Rrule" align="center" rowspan="3" valign="middle">N</th>
<th class="Rrule" align="center" colspan="2">Sorafenib  </th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center">All Grades<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Grade 3/4</th>
<th class="Rrule" align="center">All Grades<a href="#footnote-3" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Grade 3/4</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">%</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">%</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7">ALP: alkaline phosphatase; ALT: <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>; AST: <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span></td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 </dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Hematology</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin decreased</span></td>
<td class="Rrule" align="center">320</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">316</td>
<td class="Rrule" align="center">52</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">Lymphocytes</span> (absolute) decreased</td>
<td class="Rrule" align="center">317</td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">309</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Platelets decreased</td>
<td class="Rrule" align="center">312</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">310</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">White blood cells decreased</td>
<td class="Rrule" align="center">320</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">315</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Chemistry</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Creatinine increased</td>
<td class="Rrule" align="center">336</td>
<td class="Rrule" align="center">55</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">318</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> decreased</td>
<td class="Rrule" align="center">314</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">291</td>
<td class="Rrule" align="center">43</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></td>
<td class="Rrule" align="center">336</td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">319</td>
<td class="Rrule" align="center">59</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ALP increased</td>
<td class="Rrule" align="center">336</td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">319</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td class="Rrule" align="center">336</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">319</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lipase increased</td>
<td class="Rrule" align="center">338</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">319</td>
<td class="Rrule" align="center">46</td>
<td class="Rrule" align="center">15</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Amylase increased</td>
<td class="Rrule" align="center">338</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">319</td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ALT increased</td>
<td class="Rrule" align="center">331</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">313</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AST increased</td>
<td class="Rrule" align="center">331</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">311</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Hypernatremia</span></td>
<td class="Rrule" align="center">338</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">319</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span></td>
<td class="Rrule" align="center">337</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">319</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></td>
<td class="Rrule" align="center">333</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">314</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></td>
<td class="Rrule" align="center">336</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">319</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></td>
<td class="Rrule" align="center">338</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">319</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span></td>
<td class="Rrule" align="center">336</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">318</td>
<td class="Rrule" align="center">49</td>
<td class="Rrule" align="center">16</td>
</tr>
</tbody>
</table>
<p>Selected laboratory abnormalities (all grades) that were reported in &lt;10% of patients treated with INLYTA included <span class="product-label-link" type="condition" conceptid="4038953" conceptname="Increased hemoglobin">hemoglobin increased</span> (above the upper limit of normal) (9% for INLYTA versus 1% for sorafenib) and <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (6% for INLYTA versus 2% for sorafenib).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">In vitro</span> data indicate that axitinib is metabolized primarily by CYP3A4/5 and, to a lesser extent, CYP1A2, CYP2C19, and uridine diphosphate-glucuronosyltransferase (UGT) 1A1.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	CYP3A4/5 Inhibitors</h2>
<p class="First">Co-administration of ketoconazole, a strong inhibitor of CYP3A4/5, increased the plasma exposure of axitinib in healthy volunteers. Co-administration of INLYTA with strong CYP3A4/5 inhibitors should be avoided. Grapefruit or grapefruit juice may also increase axitinib plasma concentrations and should be avoided. Selection of concomitant medication with no or minimal CYP3A4/5 inhibition potential is recommended. If a strong CYP3A4/5 inhibitor must be co-administered, the INLYTA dose should be reduced <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	CYP3A4/5 Inducers</h2>
<p class="First">Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. Co-administration of INLYTA with strong CYP3A4/5 inducers (e.g., rifampin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and St. John's wort) should be avoided. Selection of concomitant medication with no or minimal CYP3A4/5 induction potential is recommended <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span> Moderate CYP3A4/5 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) may also reduce the plasma exposure of axitinib and should be avoided if possible.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category D<span class="Italics"> [see<a href="#S5.13"> Warnings and Precautions (5.13)</a>]</span>.</p>
<p>There are no adequate and well-controlled studies with INLYTA in pregnant women. INLYTA can cause fetal harm when administered to a pregnant woman based on its mechanism of action. Axitinib was teratogenic, embryotoxic and fetotoxic in mice at exposures lower than human exposures at the recommended starting dose. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Oral axitinib administered twice daily to female mice prior to mating and through the first week of pregnancy caused an increase in post-implantation loss at all doses tested (≥15 mg/kg/dose, approximately 10 times the systemic exposure (AUC) in patients at the recommended starting dose). In an embryo-fetal developmental toxicity study, pregnant mice received oral doses of 0.15, 0.5 and 1.5 mg/kg/dose axitinib twice daily during the period of organogenesis. Embryo-fetal toxicities observed in the absence of maternal toxicity included malformation (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>) at 1.5 mg/kg/dose (approximately 0.5 times the AUC in patients at the recommended starting dose) and variation in skeletal ossification at ≥0.5 mg/kg/dose (approximately 0.15 times the AUC in patients at the recommended starting dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is not known whether axitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from INLYTA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother<span class="Italics">. </span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">The safety and efficacy of INLYTA in pediatric patients have not been studied.</p>
<p>Toxicities in bone and teeth were observed in immature mice and dogs administered oral axitinib twice daily for 1 month or longer. Effects in bone consisted of thickened growth plates in mice and dogs at ≥15 mg/kg/dose (approximately 6 and 15 times, respectively, the systemic exposure (AUC) in patients at the recommended starting dose). Abnormalities in growing incisor teeth (including <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">dental caries</span>, malocclusions and broken and/or missing teeth) were observed in mice administered oral axitinib twice daily at ≥5 mg/kg/dose (approximately 1.5 times the AUC in patients at the recommended starting dose). Other toxicities of potential concern to pediatric patients have not been evaluated in juvenile animals.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">In a controlled clinical study with INLYTA for the treatment of patients with RCC, 123/359 patients (34%) treated with INLYTA were ≥65 years of age. Although greater sensitivity in some older individuals cannot be ruled out, no overall differences were observed in the safety and effectiveness of INLYTA between patients who were ≥65 years of age and younger.</p>
<p>No dosage adjustment is required in elderly patients <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In a dedicated <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> trial, compared to subjects with normal hepatic function, systemic exposure following a single dose of INLYTA was similar in subjects with baseline mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class A) and higher in subjects with baseline moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class B).</p>
<p>No starting dose adjustment is required when administering INLYTA to patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class A). A starting dose decrease is recommended when administering INLYTA to patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class B) <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2)</a>,<a href="#S5.12"> Warnings and Precautions (5.12)</a>, and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span></p>
<p>INLYTA has not been studied in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class C).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dedicated <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> trial for axitinib has been conducted. Based on the population pharmacokinetic analyses, no significant difference in axitinib clearance was observed in patients with pre-existing mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (15 mL/min ≤creatinine clearance [CLcr] &lt;89 mL/min) <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span> No starting dose adjustment is needed for patients with pre-existing mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Caution should be used in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (CLcr &lt;15 mL/min).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no specific treatment for INLYTA <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>In a controlled clinical study with INLYTA for the treatment of patients with RCC, 1 patient inadvertently received a dose of 20 mg twice daily for 4 days and experienced <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (Grade 1).</p>
<p>In a clinical dose finding study with INLYTA, subjects who received starting doses of 10 mg twice daily or 20 mg twice daily experienced adverse reactions which included <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and fatal <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>.</p>
<p>In cases of suspected <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, INLYTA should be withheld and supportive care instituted.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">INLYTA (axitinib) is a kinase inhibitor. Axitinib has the chemical name <span class="Italics">N</span>-methyl-2-[3-((<span class="Italics">E</span>)-2-pyridin-2-yl-vinyl)-1<span class="Italics">H</span>-indazol-6-ylsulfanyl]-benzamide. The molecular formula is C<span class="Sub">22</span>H<span class="Sub">18</span>N<span class="Sub">4</span>OS and the molecular weight is 386.47 Daltons. The chemical structure is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9&amp;name=inlyta-01.jpg"></div>
<p>Axitinib is a white to light-yellow powder with a pKa of 4.8. The solubility of axitinib in aqueous media over the range pH 1.1 to pH 7.8 is in excess of 0.2 µg/mL. The partition coefficient (n-octanol/water) is 3.5.</p>
<p>INLYTA is supplied as red, film-coated tablets containing either 1 mg or 5 mg of axitinib together with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and Opadry® II red 32K15441 as inactive ingredients. The Opadry II red 32K15441 film coating contains lactose monohydrate, HPMC 2910/Hypromellose 15cP, titanium dioxide, triacetin (glycerol triacetate), and red iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib <span class="Italics">in vitro</span> and in mouse models. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograft mouse models.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The effect of a single oral dose of INLYTA (5 mg) in the absence and presence of 400 mg ketoconazole on the QTc interval was evaluated in a randomized, single-blinded, two-way crossover study in 35 healthy subjects. No large changes in mean QTc interval (i.e., &gt;20 ms) from placebo were detected up to 3 hours post-dose. However, small increases in mean QTc interval (i.e., &lt;10 ms) cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First">The population pharmacokinetic analysis pooled data from 17 trials in healthy subjects and patients with cancer. A two-compartment disposition model with first-order absorption and lag-time adequately describes the axitinib concentration-time profile.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption and Distribution:</span> Following single oral 5-mg dose administration, the median T<span class="Sub">max</span> ranged from 2.5 to 4.1 hours. Based on the plasma half-life, steady state is expected within 2 to 3 days of dosing. Dosing of axitinib at 5 mg twice daily resulted in approximately 1.4-fold accumulation compared to administration of a single dose. At steady state, axitinib exhibits approximately linear pharmacokinetics within the 1-mg to 20-mg dose range. The mean absolute bioavailability of axitinib after an oral 5 mg dose is 58%.</p>
<p>Compared to overnight fasting, administration of INLYTA with a moderate fat meal resulted in 10% lower AUC and a high fat, high-calorie meal resulted in 19% higher AUC. INLYTA can be administered with or without food <span class="Italics">[see<a href="#S2.1"> Dosage and Administration (2.1)</a>].</span></p>
<p>Axitinib is highly bound (&gt;99%) to human plasma proteins with preferential binding to albumin and moderate binding to α<span class="Sub">1</span>-acid glycoprotein. In patients with advanced RCC (n=20), at the 5 mg twice daily dose in the fed state, the geometric mean (CV%) C<span class="Sub">max</span> and AUC<span class="Sub">0–24</span> were 27.8 (79%) ng/mL and 265 (77%) ng.h/mL, respectively. The geometric mean (CV%) clearance and apparent volume of distribution were 38 (80%) L/h and 160 (105%) L, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Metabolism and Elimination:</span> The plasma half life of INLYTA ranges from 2.5 to 6.1 hours. Axitinib is metabolized primarily in the liver by CYP3A4/5 and to a lesser extent by CYP1A2, CYP2C19, and UGT1A1. Following oral administration of a 5-mg radioactive dose of axitinib, approximately 41% of the radioactivity was recovered in feces and approximately 23% was recovered in urine. Unchanged axitinib, accounting for 12% of the dose, was the major component identified in feces. Unchanged axitinib was not detected in urine; the carboxylic acid and sulfoxide metabolites accounted for the majority of radioactivity in urine. In plasma, the N-glucuronide metabolite represented the predominant radioactive component (50% of circulating radioactivity) and unchanged axitinib and the sulfoxide metabolite each accounted for approximately 20% of the circulating radioactivity.</p>
<p>The sulfoxide and N-glucuronide metabolites show approximately ≥400-fold less <span class="Italics">in vitro</span> potency against VEGFR-2 compared to axitinib.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Drug-Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.1"></a><p></p>
<p class="First"><span class="Underline">Effects of Other Drugs on INLYTA:</span>  Axitinib is metabolized primarily in the liver by CYP3A4/5. Additionally, the aqueous solubility of axitinib is pH dependent, with higher pH resulting in lower solubility. The effects of a strong CYP3A4/5 inhibitor, a strong CYP3A4/5 inducer, and an antacid on the pharmacokinetics of axitinib are presented in Figure 1 <span class="Italics"> [see<a href="#S2.2"> Dosage and Administration (2.2) </a>and<a href="#S7.1"> Drug Interactions (7.1</a>,<a href="#S7.2"> 7.2)</a>].</span></p>
<p><span class="Bold">Figure 1. Impact of Co-administered Drugs and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> on Axitinib Pharmacokinetics</span></p>
<p><a name="fig1"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9&amp;name=inlyta-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.2"></a><p></p>
<p class="First"><span class="Underline">Effects of INLYTA on Other Drugs:</span><span class="Italics">  In vitro</span> studies demonstrated that axitinib has the potential to inhibit CYP1A2 and CYP2C8. However, co-administration of axitinib with paclitaxel, a CYP2C8 substrate, did not increase plasma concentrations of paclitaxel in patients.</p>
<p><span class="Italics">In vitro</span> studies indicated that axitinib does not inhibit CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, or UGT1A1 at therapeutic plasma concentrations. <span class="Italics">In vitro</span> studies in human hepatocytes indicated that axitinib does not induce CYP1A1, CYP1A2, or CYP3A4/5.</p>
<p>Axitinib is an inhibitor of the efflux transporter P-glycoprotein (P-gp) <span class="Italics">in vitro</span>. However, INLYTA is not expected to inhibit P-gp at therapeutic plasma concentrations.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics in Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Underline">Pediatric Use:</span>  INLYTA has not been studied in patients &lt;18 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span>  The effects of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of axitinib are presented in Figure 1 <span class="Italics"> [see<a href="#S2.2"> Dosage and Administration (2.2)</a>,<a href="#S5.12"> Warnings and Precautions (5.12)</a>, and<a href="#S8.6"> Use in Specific Populations (8.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Population pharmacokinetic analysis (based on pre-existing renal function) was carried out in 590 healthy volunteers and patients, including five with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (15 mL/min ≤CLcr &lt;29 mL/min), 64 with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (30 mL/min ≤CLcr &lt;59 mL/min), and 139 with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (60 mL/min ≤CLcr &lt;89 mL/min). Mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> did not have meaningful effects on the pharmacokinetics of axitinib. Data from only one patient with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> are available <span class="Italics">[see<a href="#S8.7"> Use in Specific Populations (8.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.4"></a><p></p>
<p class="First"><span class="Underline">Other Intrinsic Factors:</span>  Population pharmacokinetic analyses indicate that there are no clinically relevant effects of age, gender, race, body weight, body surface area, UGT1A1 genotype, or CYP2C19 genotype on the clearance of axitinib.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been conducted with axitinib.</p>
<p>Axitinib was not mutagenic in an <span class="Italics">in vitro</span> bacterial reverse mutation (Ames) assay and was not clastogenic in the <span class="Italics">in vitro</span> human lymphocyte chromosome aberration assay. Axitinib was genotoxic in the <span class="Italics">in vivo</span> mouse bone marrow micronucleus assay.</p>
<p>INLYTA has the potential to impair reproductive function and fertility in humans. In repeat-dose toxicology studies, findings in the male reproductive tract were observed in the testes/epididymis (decreased organ weight, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> or degeneration, decreased numbers of germinal cells, hypospermia or abnormal sperm forms, reduced sperm density and count) at  ≥15 mg/kg/dose administered orally twice daily in mice (approximately 7 times the systemic exposure (AUC) in patients at the recommended starting dose) and ≥1.5 mg/kg/dose administered orally twice daily in dogs (approximately 0.1 times the AUC in patients at the recommended starting dose). Findings in the female reproductive tract in mice and dogs included signs of delayed sexual maturity, reduced or absent corpora lutea, decreased uterine weights and uterine <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> at ≥5 mg/kg/dose (approximately 1.5 or 0.3 times the AUC in patients at the recommended starting dose compared to mice and dogs, respectively).</p>
<p>In a fertility study in mice, axitinib did not affect mating or fertility rate when administered orally twice daily to males at any dose tested up to 50 mg/kg/dose following at least 70 days of administration (approximately 57 times the AUC in patients at the recommended starting dose). In female mice, reduced fertility and embryonic viability were observed at all doses tested (≥15 mg/kg/dose administered orally twice daily) following at least 15 days of treatment with axitinib (approximately 10 times the AUC in patients at the recommended starting dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of INLYTA were evaluated in a randomized, open-label, multicenter Phase 3 study. Patients (N=723) with advanced RCC whose disease had progressed on or after treatment with 1 prior systemic therapy, including sunitinib-, bevacizumab-, temsirolimus-, or cytokine-containing regimens were randomized (1:1) to receive INLYTA (N=361) or sorafenib (N=362). Progression-free survival (PFS) was assessed by a blinded independent central review committee. Other endpoints included objective response rate (ORR) and overall survival (OS).</p>
<p>Of the patients enrolled in this study, 389 patients (54%) had received 1 prior sunitinib-based therapy, 251 patients (35%) had received 1 prior cytokine-based therapy (interleukin-2 or interferon-alfa), 59 patients (8%) had received 1 prior bevacizumab-based therapy, and 24 patients (3%) had received 1 prior temsirolimus-based therapy. The baseline demographic and disease characteristics were similar between the INLYTA and sorafenib groups with regard to age (median 61 years), gender (72% male), race (75% white, 21% Asian), Eastern Cooperative Oncology Group (ECOG) performance status (55% 0, 45% 1), and histology (99% clear cell).</p>
<p>There was a statistically significant advantage for INLYTA over sorafenib for the endpoint of PFS (see<a href="#table3"> Table 3 </a>and<a href="#fig2"> Figure 2</a>). There was no statistically significant difference between the arms in OS.</p>
<a name="table3"></a><table width="100%">
<caption><span>Table 3. Efficacy Results</span></caption>
<col align="left" valign="top" width="32%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Endpoint/Study Population</th>
<th class="Rrule" align="center">INLYTA</th>
<th class="Rrule" align="center">Sorafenib</th>
<th class="Rrule" align="center">HR (95% CI)</th>
<th class="Rrule" align="center">P-value</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">CI: Confidence interval; HR: Hazard ratio (INLYTA/sorafenib); ITT: Intent to treat; ORR: Objective response rate; NS: Not significant; OS: Overall survival; PFS: Progression-free survival</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Time from randomization to progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to any cause, whichever occurs first. </dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Assessed by independent radiology review according to RECIST. </dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>One-sided p-value from a log-rank test of treatment stratified by ECOG performance status and prior therapy (comparison is considered statistically significant if the one-sided p-value is &lt;0.023). </dd>
<dt><a name="footnote-7" href="#footnote-reference-7">§</a></dt>
<dd>Risk ratio is used for ORR. A risk ratio &gt;1 indicated a higher likelihood of responding in the axitinib arm; a risk ratio &lt;1 indicated a higher likelihood of responding in the sorafenib arm.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">¶</a></dt>
<dd>P-value not included since it was not adjusted for multiple testing.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Overall ITT</span></td>
<td class="Rrule" align="center">N= 361</td>
<td class="Rrule" align="center">N = 362</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median PFS<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a> in months (95% CI)</td>
<td class="Rrule" align="center">6.7 (6.3, 8.6)</td>
<td class="Rrule" align="center">4.7 (4.6, 5.6)</td>
<td class="Rrule" align="center">0.67 (0.54, 0.81)</td>
<td class="Rrule" align="center">&lt;0.0001<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median OS in months (95% CI)</td>
<td class="Rrule" align="center">20.1 (16.7, 23.4)</td>
<td class="Rrule" align="center">19.2 (17.5, 22.3)</td>
<td class="Rrule" align="center">0.97 (0.80, 1.17)</td>
<td class="Rrule" align="center">NS</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ORR % (95% CI)</td>
<td class="Rrule" align="center">19.4 (15.4, 23.9)</td>
<td class="Rrule" align="center">9.4 (6.6, 12.9)</td>
<td class="Rrule" align="center">2.06<a name="footnote-reference-7" href="#footnote-7" class="Sup">§</a> (1.41, 3.00)</td>
<td class="Rrule" align="center">-<a name="footnote-reference-8" href="#footnote-8" class="Sup">¶</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">PFS by prior treatment</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sunitinib-refractory subgroup</td>
<td class="Rrule" align="center">N=194</td>
<td class="Rrule" align="center">N=195</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Median, months (95% CI)</td>
<td class="Rrule" align="center">4.8 (4.5, 6.4)</td>
<td class="Rrule" align="center">3.4 (2.8, 4.7)</td>
<td class="Rrule" align="center">0.74 (0.57, 0.96)</td>
<td class="Rrule" align="center">-<a href="#footnote-8" class="Sup">¶</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cytokine-refractory subgroup</td>
<td class="Rrule" align="center">N=126</td>
<td class="Rrule" align="center">N=125</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">  Median, months (95% CI)</td>
<td class="Rrule" align="center">12.1 (10.1, 13.9)</td>
<td class="Rrule" align="center">6.5 (6.3, 8.3)</td>
<td class="Rrule" align="center">0.46 (0.32, 0.68)</td>
<td class="Rrule" align="center">-<a href="#footnote-8" class="Sup">¶</a>
</td>
</tr>
</tbody>
</table>
<p><a name="fig2"></a><span class="Bold">Figure 2. Kaplan-Meier Curve for Progression Free Survival by Independent Assessment (Intent-to-Treat Population)</span></p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9&amp;name=inlyta-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">INLYTA tablets are supplied as follows:</p>
<p>1 mg tablets are red film-coated, oval tablets debossed with "Pfizer" on one side and "1 XNB" on the other; available in bottles of 180: NDC 0069-0145-01.</p>
<p>5 mg tablets are red film-coated, triangular tablets debossed with "Pfizer" on one side and "5 XNB" on the other; available in bottles of 60: NDC 0069-0151-11.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">Advise the patient to read the FDA-approved patient labeling (Patient Information)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Advise patients that <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may develop during INLYTA treatment and that blood pressure should be monitored regularly during treatment <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2	Arterial/Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span></h2>
<p class="First">Advise patients that arterial and venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> have been observed during INLYTA treatment and to inform their doctor if they experience symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> <span class="Italics">[see<a href="#S5.2"> Warnings and Precautions (5.2</a>,<a href="#S5.3"> 5.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></h2>
<p class="First">Advise patients that INLYTA may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and to promptly inform their doctor of any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes <span class="Italics">[see<a href="#S5.4"> Warnings and Precautions (5.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4	<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Advise patients that <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> may develop during INLYTA treatment and that signs or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> should be regularly monitored for during treatment <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5	<span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></h2>
<p class="First">Advise patients that <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> may develop during INLYTA treatment and to seek immediate medical attention if they experience persistent or severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> because cases of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span> have been reported in patients taking INLYTA <span class="Italics">[see<a href="#S5.6"> Warnings and Precautions (5.6) </a>and<a href="#S6.1"> Adverse Reactions (6.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6	Abnormal Thyroid Function</h2>
<p class="First">Advise patients that abnormal thyroid function may develop during INLYTA treatment and to inform their doctor if symptoms of abnormal thyroid function occur <span class="Italics">[see<a href="#S5.7"> Warnings and Precautions (5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.7"></a><a name="section-15.7"></a><p></p>
<h2>17.7	<span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing Complications</h2>
<p class="First">Advise patients to inform their doctor if they have an unhealed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> or if they have surgery scheduled <span class="Italics">[see<a href="#S5.8"> Warnings and Precautions (5.8)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.8"></a><a name="section-15.8"></a><p></p>
<h2>17.8   	<span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span></h2>
<p class="First">Advise patients to inform their doctor if they have worsening of neurological function consistent with RPLS (<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and other visual and neurologic disturbances) <span class="Italics">[see<a href="#S5.9"> Warnings and Precautions (5.9)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.9"></a><a name="section-15.9"></a><p></p>
<h2>17.9	Pregnancy</h2>
<p class="First">Advise patients that INLYTA can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> or fetal loss and that they should not become pregnant during treatment with INLYTA. Both male and female patients should be counseled to use effective birth control during treatment with INLYTA. Female patients should also be advised against breast-feeding while receiving INLYTA <span class="Italics">[</span><span class="Italics">see<a href="#S5.13"> Warnings and Precautions (5.13) </a>and<a href="#S8.3"> Use in Specific Populations (8.3)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.10"></a><a name="section-15.10"></a><p></p>
<h2>17.10	Concomitant Medications</h2>
<p class="First">Advise patients to inform their doctor of all concomitant medications, vitamins, or dietary and herbal supplements.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9&amp;name=inlyta-04.jpg"></p>
<p>LAB- 0561-3.0</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-17"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First">INLYTA<span class="Sup">®</span> (in-ly-ta)<br>(axitinib)<br>tablets</p>
<p>Read this Patient Information before you start taking INLYTA and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is INLYTA?</span></p>
<p>INLYTA is a prescription medicine used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC) when one prior drug treatment for this disease has not worked.</p>
<p>It is not known if INLYTA is safe or effective in children.</p>
<p><span class="Bold">What should I tell my doctor before taking INLYTA?</span></p>
<p>Before you take INLYTA, tell your doctor if you:</p>
<ul>
<li> have high blood pressure</li>
<li> have thyroid problems</li>
<li> have liver problems</li>
<li> have a history of blood clots in your veins or arteries (types of blood vessels), including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, or change in vision</li>
<li> have any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li> have a history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></li>
<li> have an unhealed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> </li>
<li> plan to have surgery. You should stop taking INLYTA at least 24 hours before planned surgery.</li>
<li> have any other medical conditions</li>
</ul>
<p><span class="Bold">For females, tell your doctor if you:</span></p>
<ul>
<li>are pregnant or plan to become pregnant. Taking INLYTA during pregnancy can cause the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of an unborn baby or <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. You should not become pregnant while taking INLYTA. Talk to your doctor if you are pregnant or plan to become pregnant. </li>
<li>are able to become pregnant. You should use effective birth control during your treatment with INLYTA. Talk to your doctor about birth control methods to prevent pregnancy while you are taking INLYTA.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if INLYTA passes into your breast milk. You and your doctor should decide if you will take INLYTA or breastfeed. You should not do both.</li>
</ul>
<p><span class="Bold">For males:</span></p>
<ul>
<li>use effective birth control during your treatment with INLYTA. Talk to your doctor about birth control methods.</li>
<li>if your female partner becomes pregnant while you are taking INLYTA, tell your doctor right away.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements. INLYTA and certain other medicines can affect each other causing serious side effects.</p>
<p>Especially tell your doctor if you take:</p>
<ul class="Disc">
<li> dexamethasone</li>
<li> bosentan</li>
<li> modafinil</li>
<li> St. John's wort (Hypericum perforatum)</li>
<li> Medicine for:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> </li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> </li>
<li><span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>  </li>
<li><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> </li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>HIV or AIDS</li>
</ul>
</li>
</ul>
<p>Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. If you are taking any medicines for the conditions listed above, your doctor might need to prescribe a different medicine or your dose of INLYTA may need to be changed. Talk with your doctor before you start taking any new medicine.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take INLYTA?</span></p>
<ul>
<li> Take INLYTA exactly as prescribed by your doctor.</li>
<li> Your doctor may change your dose if needed.</li>
<li> INLYTA can be taken with or without food.</li>
<li> Take INLYTA 2 times a day about 12 hours apart.</li>
<li> Swallow INLYTA tablets whole with a glass of water.</li>
<li> Your doctor should check your blood pressure regularly during treatment with INLYTA.</li>
<li> If you vomit or miss a dose of INLYTA, take your next dose at your regular time. Do not take two doses at the same time.</li>
<li>If you take too much INLYTA, call your doctor or go to the nearest hospital emergency room right away.</li>
</ul>
<p><span class="Bold">What should I avoid while taking INLYTA?</span></p>
<ul class="Disc"><li>Do not drink grapefruit juice or eat grapefruit. Grapefruit may increase the amount of INLYTA in your blood.</li></ul>
<p><span class="Bold">What are the possible side effects of INLYTA?</span></p>
<p>INLYTA may cause serious side effects, including:</p>
<ul class="Disc">
<li>
<span class="Bold">High blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>). </span>Your doctor should check your blood pressure regularly during treatment with INLYTA. If you develop blood pressure problems, your doctor may prescribe medicine to treat your high blood pressure, lower your dose, or stop your treatment with INLYTA.</li>
<li>
<span class="Bold">Problem with blood clots in your veins or arteries.</span> INLYTA can cause blood clots which can be serious, and sometimes lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Get emergency help and call your doctor if you get any of the following symptoms:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or pressure</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your arms, back, neck or jaw</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on one side of your body</li>
<li>trouble talking</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li>vision changes</li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>.</span> INLYTA can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which can be serious, and sometimes lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Call your doctor right away or get medical help if you develop any of the following signs or symptoms: 								<ul class="Disc">
<li>unexpected <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that lasts a long time, such as: 										<ul class="Disc">
<li>unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the gums</li>
<li>menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> that is heavier than normal</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that is severe or you cannot control</li>
<li>pink or brown urine</li>
<li>red or <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span> (looks like tar)</li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> that happen without a known cause or get larger</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> up blood or blood clots</li>
<li>vomit blood or your vomit looks like "coffee grounds"</li>
</ul>
</li>
<li>unexpected <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, feeling dizzy or weak</li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span>. </span> Your doctor should check for signs or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> regularly during treatment with INLYTA. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> can be serious and can sometimes lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Tell your doctor if you have any of the following symptoms during your treatment with INLYTA: <ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your stomach-area (abdomen), legs or ankles</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li>protruding neck veins</li>
</ul>
</li>
<li>
<span class="Bold">Tear in your stomach or intestinal wall (perforation). </span> A tear in your stomach or intestinal wall can be serious and can sometimes lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Get medical help right away if you get the following symptoms: <ul class="Disc">
<li>severe stomach (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> that does not go away</li>
<li>vomit blood</li>
<li>red or <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span> </li>
</ul>
</li>
<li>
<span class="Bold">Thyroid gland problems. </span> Your doctor should do blood tests to check your thyroid gland function before and during your treatment with INLYTA. Tell your doctor if you have any of the following symptoms during your treatment with INLYTA:  <ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> that worsens or that does not go away</li>
<li><span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling hot</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span></li>
<li>your voice deepens</li>
<li><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span></li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span> (RPLS).</span> A condition called <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">reversible posterior leukoencephalopathy syndrome</span> (RPLS) can happen while taking INLYTA. Call your doctor right away if you get:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> or change in vision </li>
<li>problems thinking</li>
</ul>
</li>
<li>
<span class="Bold"> Increased protein in your urine. </span>Your doctor should check your urine for protein before and during your treatment with INLYTA. If you develop protein in your urine, your doctor may decrease your dose of INLYTA or stop your treatment.</li>
<li>
<span class="Bold">Change in liver function. </span>Your doctor should do blood tests before and during your treatment with INLYTA to check your liver function.</li>
</ul>
<p><span class="Bold">The most common side effects of INLYTA include:</span></p>
<ul>
<li> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (frequent or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose bowel</span> movements)</li>
<li> high blood pressure</li>
<li> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> or feeling weak</li>
<li> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></li>
<li> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li> <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span></li>
<li> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of your skin on your hands and feet</li>
<li> decreased weight</li>
<li> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of INLYTA. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store INLYTA?</span></p>
<ul class="Disc"><li>Store INLYTA at room temperature between 68°F to 77°F (20°C to 25°C).</li></ul>
<p><span class="Bold">Keep INLYTA and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about INLYTA.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use INLYTA for a condition for which it was not prescribed. Do not give INLYTA to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about INLYTA. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about INLYTA that is written for health professionals. </p>
<p>For more information, go to www.inlyta.com or call 877-744-5675. </p>
<p><span class="Bold">What are the ingredients in INLYTA? </span></p>
<p><span class="Bold">Active ingredient: </span> axitinib</p>
<p><span class="Bold">Inactive ingredients: </span> microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and Opadry® II red 32K15441. The Opadry II red 32K15441 film coating contains: lactose monohydrate, HPMC 2910/Hypromellose 15cP, titanium dioxide, triacetin (glycerol triacetate), and red iron oxide.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<p class="First">This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9&amp;name=inlyta-04.jpg"></p>
<p>LAB-0439-3.0</p>
<p>08/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1 mg Bottle Label</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0069-0145-01</p>
<p><span class="Bold">Inlyta</span><span class="Sup">®</span><br><span class="Bold">(axitinib) tablets</span></p>
<p><span class="Bold">1 mg</span></p>
<p>180 Tablets</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 1 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9&amp;name=inlyta-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg Bottle Label</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0069-0151-11</p>
<p><span class="Bold">Inlyta</span><span class="Sup">®</span><br><span class="Bold">(axitinib) tablets</span></p>
<p><span class="Bold">5 mg</span></p>
<p>60 Tablets</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9&amp;name=inlyta-06.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INLYTA 		
					</strong><br><span class="contentTableReg">axitinib tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0145</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AXITINIB</strong> (AXITINIB) </td>
<td class="formItem">AXITINIB</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;1;XNB</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0145-01</td>
<td class="formItem">180  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202324</td>
<td class="formItem">01/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INLYTA 		
					</strong><br><span class="contentTableReg">axitinib tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0151</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AXITINIB</strong> (AXITINIB) </td>
<td class="formItem">AXITINIB</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TRIANGLE</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;5;XNB</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0151-11</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202324</td>
<td class="formItem">01/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc
							(134489525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Ireland Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">989811526</td>
<td class="formItem">ANALYSIS(0069-0151, 0069-0145), API MANUFACTURE(0069-0151, 0069-0145)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Pharmaceuticals LLC</td>
<td class="formItem"></td>
<td class="formItem">829084552</td>
<td class="formItem">ANALYSIS(0069-0151, 0069-0145), PACK(0069-0151, 0069-0145)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Manufacturing Deutschland GmbH (Betriebsstätte Freiburg)</td>
<td class="formItem"></td>
<td class="formItem">341970073</td>
<td class="formItem">ANALYSIS(0069-0151, 0069-0145), LABEL(0069-0151, 0069-0145), MANUFACTURE(0069-0151, 0069-0145), PACK(0069-0151, 0069-0145)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>80b780b7-5c6b-415f-b2ef-14cbd9a22768</div>
<div>Set id: 84137882-e000-47da-bd5b-fa76ab3c76f9</div>
<div>Version: 9</div>
<div>Effective Time: 20140814</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc</div></p>
</body></html>
